ERRATA

The September 1, 2008, article by Goldstein et al, entitled “Prognostic Utility of the 21-Gene Assay in Hormone Receptor–Positive Operable Breast Cancer Compared With Classical Clinicopathologic Features” (J Clin Oncol 26:4063-4071, 2008), contained errors.

The Running Head was given as: “21-Gene Assay Compared With Adjuvant!”

While it should have been: “21-Gene Assay Compared With Clinicopathologic Features.”

In Figures 2, 3, 4(B & C), and 5(A), the term “Adjuvant!” was used, whereas it should have been “Integrator.”

The online version has been corrected in departure from the print.

DOI: 10.1200/JCO.2009.24.7387

In the May 20, 2009, supplement, the abstract by Bruix et al, entitled “Effect of macroscopic vascular invasion (MVI), extrahepatic spread (EHS), and ECOG performance status (ECOG PS) on outcome in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib: Analysis of two phase III, randomized, double-blind trials” (J Clin Oncol 27:521s, 2009 [suppl; abstr 4580]), contained errors.

In the table, the disease-control rate (DCR) for ECOG 1/2 was inadvertently omitted and should have been 33.9% for sorafenib and 12.7% for placebo.

The online version has been corrected in departure from the print.

DOI: 10.1200/JCO.2009.24.7395

In the May 20, 2009, supplement, the abstract by Qin et al, entitled “Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma (HCC): Asia-Pacific (AP) Trial subgroup analyses by baseline transaminase (ALT/AST)/ α -fetoprotein (AFP) levels” (J Clin Oncol 27:521s, 2009 [suppl; abstr 4590]), contained errors.

In the table, overall survival (OS) for elevated AFP ($> 40 \mu\text{g/L}$) was inadvertently omitted. The median values should have been 5.9 months for sorafenib and 4.1 months for placebo, and the hazard ratio (HR) value should have been 0.65 (95% CI, 0.45 to 0.93). Also, the disease-control rate (DCR) for elevated AFP ($> 40 \mu\text{g/L}$) was inadvertently omitted and should have been 35.1% for sorafenib and 9.3% for placebo.

The online version has been corrected in departure from the print.

DOI: 10.1200/JCO.2009.24.7403

In the May 20, 2009, supplement, the abstract by Fukuoka et al, entitled “Biomarker analyses from a phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non–small-cell lung cancer (NSCLC) in Asia (IPASS)” (J Clin Oncol 27:521s, 2009 [suppl; abstr 8006]), contained errors.

In the table, the objective response rate (ORR) for PE unknown was inadvertently omitted. The ORR% should have been 41.5% for G and 29.9% for CP. The OR G:CP value should have been 1.66. The 95% CI should have been 1.25 to 2.22. The *P*-value should have been .0005.